US2020377591A1PendingUtilityA1

Markers of acute myeloid leukemia stem cells

75
Assignee: UNIV LELAND STANFORD JUNIORPriority: Jan 15, 2008Filed: Apr 20, 2020Published: Dec 3, 2020
Est. expiryJan 15, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Ravindra MajetiIrving L. Weissman
G01N 33/57505A61K 2039/505C07K 16/2896C07K 2317/76C07K 16/2803C12Q 1/6886C12Q 2600/112C07K 2317/24C12N 5/0694C07K 2317/75C12N 5/0093C12Q 2600/136G01N 2500/04A61K 2039/507C07K 16/28G01N 33/5011A61P 35/02C07K 16/30C07K 2317/73G01N 33/57426
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Claims

exact text as granted — not AI-modified
1 . A method for characterizing an acute myeloid leukemia from a patient, the method comprising:
 contacting a patient sample with reagents specific for a differentially expressed marker or combination of markers set forth in Table 1;   quantitating the number of marker expressing cancer cells,   wherein the presence of marker expressing cancer cells is indicative of the presence of AML stem cells (AMLSC).   
     
     
         2 - 19 . (canceled)

Join the waitlist — get patent alerts

Track US2020377591A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.